Sign In
Buy CABA
$3.58
-0.100 (-2.72%)
At Close: Jun 03, 2026
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
08:00am, Thursday, 05'th Feb 2026
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell the
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?
01:00pm, Friday, 30'th Jan 2026
Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cabaletta Bio: Do You Buy With The Insiders?
11:01am, Tuesday, 27'th Jan 2026
Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidenc
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 27'th Jan 2026
Here is how Cabaletta Bio, Inc. (CABA) and Celcuity, Inc. (CELC) have performed compared to their sector so far this year.
Cabaletta Bio Announces 2026 Strategic Priorities
08:00am, Monday, 12'th Jan 2026
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
07:30am, Monday, 12'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio's (Nasdaq: CABA) investigational CAR
Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
05:23pm, Wednesday, 03'rd Dec 2025
Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
07:30am, Monday, 10'th Nov 2025
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
08:00am, Tuesday, 04'th Nov 2025
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October
01:58am, Monday, 03'rd Nov 2025
Cabaletta Bio, Inc. (NASDAQ: CABA - Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 11,220,000 shares, a grow
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
07:00am, Monday, 27'th Oct 2025
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
08:00am, Tuesday, 14'th Oct 2025
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE)
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators
Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon
06:20am, Tuesday, 07'th Oct 2025
Cabaletta Bio (CABA) offers pioneering CAR T-cell therapy for autoimmune diseases, with recent data showing promising efficacy and manageable safety. CABA's lead candidate, rese-cel, has demonstrated
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
08:00am, Wednesday, 27'th Aug 2025
PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
